---
title: "Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275035118.md"
description: "Bristol Myers Squibb Co. (BMY) shares rose 3.30% to $59.52 on a challenging trading day for the market, with the S&P 500 and Dow Jones falling 1.23% and 1.20%, respectively. This marks the fifth consecutive day of gains for BMY, which is currently 6.02% below its 52-week high of $63.33. The stock outperformed competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories. Trading volume reached 23.9 million, surpassing the 50-day average of 14.6 million."
datetime: "2026-02-05T21:39:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275035118.md)
  - [en](https://longbridge.com/en/news/275035118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275035118.md)
generator: "portal-rs"
---

# Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Bristol Myers Squibb Co. (BMY) advanced 3.30% to $59.52 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 1.23% to 6,798.40 and Dow Jones Industrial Average falling 1.20% to 48,908.72.

This was the stock's fifth consecutive day of gains.

Bristol Myers Squibb Co. closed 6.02% below its 52-week high of $63.33, which the company achieved on March 11th.

The stock outperformed some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 1.42% to $237.79, Pfizer Inc. (PFE) fell 1.08% to $26.49, and Abbott Laboratories (ABT) rose 0.81% to $109.08.

Trading volume (23.9 M) eclipsed its 50-day average volume of 14.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 5, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-05-26 1639ET

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABL.US](https://longbridge.com/en/quote/ABL.US.md)

## Related News & Research

- [Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson (JNJ)?](https://longbridge.com/en/news/298140186.md)
- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [Bristol-Myers Squibb (BMY) Following Camzyos Data And Zola Cel Pause Still Looks Fully Valued](https://longbridge.com/en/news/298117403.md)
- [Will Long‑Term Camzyos Data and Real‑World Evidence Change Bristol Myers Squibb's (BMY) Narrative?](https://longbridge.com/en/news/298073103.md)
- [Continuous glucose monitors are about to get more complicated](https://longbridge.com/en/news/297807418.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**